Efficacy Produced from Olverembatinib in Ponatinib-Resistant, T25I-Mutant CML, and Ph-Positive ALL
December 13th 2022Those with chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and those with CML whose tumors have a T315I mutation, were found to have improved efficacy when olverembatinib was given.
Despite Similar Recurrence Scores, Black Patients With HR+ Breast Cancer Have Worse Outcomes
December 7th 2022Non-Hispanic Black patients with HR+ breast cancer experienced worse overall outcomes compared with other patient subgroups despite similar recurrence scores, according to a recent analysis of the phase 3 RxPONDER trial.